Catalog No.: PC-61597Not For Human Use, Lab Use Only.
CK-101 (Olafertinib, RX-518) is a novel potent, mutant-selective, irreversible, orally available EGFR inhibitor, overcomes T790M-mediated resistance in NSCLC.
CK-101 (Olafertinib, RX-518) is a novel potent, mutant-selective, irreversible, orally available EGFR inhibitor, overcomes T790M-mediated resistance in NSCLC.
CK-101 (Olafertinib, RX-518) specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward WT EGFR.
CK-101 (Olafertinib, RX-518) selectively inhibits cell proliferation of cell lines expressing both the activating (HCC827, IC50 <15 nM) and resistance mutations (NCI-H1975, IC50 <5 nM).
CK-101 (Olafertinib, RX-518) significantly inhibits tumor growth in EGFR-mutated NSCLC tumor xenograft models, with no activity in WT EGFR tumor xenograft model.
1. Xiangping Qian, et al. Abstract 2078: CK-101 (RX518), a mutant-selective inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. DOI: 10.1158/1538-7445.AM2017-2078
